Oncology Care Model Linked to Reduced Therapy in Poor-Prognosis Cancer

The clinical landscape of oncology is currently defined by a tension between rising incidence rates for several major cancers and a steady decline in overall mortality driven by therapeutic advances (8, 9). As the population of cancer survivors grows and the demographic ages, the healthcare system faces increasing pressure to deliver high-quality care while managing escalating costs (11, 14). Historically, fee-for-service structures have been criticized for prioritizing the volume of interventions over the value of patient outcomes. To address this, the Centers for Medicare and Medicaid Services introduced alternative payment models designed to align financial incentives with efficient, evidence-based practice (17, 18). However, concerns remain that episode-based payments might inadvertently encourage clinicians to initiate systemic therapy more frequently to trigger care management fees. A recent study examines whether these reimbursement shifts actually influenced the likelihood of starting systemic treatment across different patient populations.